Prelude Therapeutics Financial Overview
Prelude Therapeutics's market cap is currently $126.25M. The company's EPS TTM is $-0.26; its P/E ratio is -1.52; Prelude Therapeutics is scheduled to report earnings on November 12, 2025, and the estimated EPS forecast is $-0.13. See an overview of income statement, balance sheet, and cash flow financials.
